UFC women’s flyweight Erin Blanchfield has been issued a public warning by USADA (the U.S. Anti-Doping Agency) following use of a prescribed medication without approval.
USADA oversees the UFC’s Anti-Doping Policy, which has an established process for athletes to obtain a Therapeutic Use Exemption (TUE) for prescribed medications that would otherwise be treated as banned substances.
In a press release issued Friday, USADA officials announced that “Blanchfield’s violation resulted from her use of topical spironolactone, a prescription medication, which she used under the care of a dermatologist for a diagnosed medical condition.”
Blanchfield had not obtained a TUE for the substance, but was subsequently granted one “through the established process” in order to continue using the medication.
Friday’s pres release did not specify whether Blanchfield had initially declared use of the medication, or if the compound had turned up as part of USADA’s testing regime.
Blanchfield (8-1) last competed in December 2021, where she secured a unanimous decision win over fellow flyweight prospect Miranda Maverick. She’s next expected to face JJ Aldrich on June 4, 2022. An Invicta FC veteran, Erin Blanchfield has won both her UFC fights to date. The lone loss on her professional record came against Tracy Cortez — who now competes in the UFC as well.
